Evidence map›Paper›PMID 41526683›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2026

Measuring Neural Factor X Pathway Activity in Rodent Glioma Cell Culture and Brain Slices.

Valery Golderman, Shany Guly Gofrit, Maya Schiller, Joab Chapman, Efrat Shavit-Stein

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Valery GoldermanDepartment of Neurology, The Chaim Sheba Medical Center, 52626202, Ramat Gan, Israel.
Shany Guly GofritDepartment of Neurology, The Chaim Sheba Medical Center, 52626202, Ramat Gan, Israel. shanygo@gmail.com.ORCID http://orcid.org/0000-0001-6104-606X
Maya SchillerDepartment of Neurology, The Chaim Sheba Medical Center, 52626202, Ramat Gan, Israel.
Joab ChapmanDepartment of Neurology and Neurosurgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Tel Aviv, Israel.
Efrat Shavit-SteinDepartment of Neurology and Neurosurgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Tel Aviv, Israel. shavitef@tauex.tau.ac.il.ORCID http://orcid.org/0000-0003-3373-8397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coagulation factor X (FX) plays a significant role in neuroinflammation and is considered a promising target for therapeutic intervention. However, because activated FX (FXa) levels in neural tissues are expected to be significantly lower than in plasma, a more sensitive, direct, and specific method is required for accurate detection. To measure FXa activity with high sensitivity, we used a fluorogenic substrate in combination with a panel of specific inhibitors to prevent nonspecific protease activity that potentially cleaves the substrate, initially validated in human normal and FX-deficient plasma. This approach allowed selective quantification of FXa activity in neural samples. To further characterize the FX pathway, we applied a FXa inhibitor (apixaban), a FX activator (Russell's viper venom X, RVVX), and commercially available FX and FXa to mouse brain slices and to glioma cell lines derived from human, rat, and mouse. FXa activity significantly increased following RVVX application in human plasma and mouse brain and was inhibited in a calcium-dependent manner in human plasma. In the mouse brain, apixaban inhibited only the FXa activity secreted from the slice rather than the slice-associated activity. In glioma cell lines, RVVX application increased cell-bound FXa activity, which was not inhibited by apixaban, while the activity secreted into the medium was elevated and inhibited by apixaban. Exposure to lipopolysaccharide reduced RVVX-induced FXa activity while increasing the thrombin activity in glioma cell lines from mice and rats, respectively. We developed a specific method of measuring basal FXa activity and induced from FX by RVVX, in plasma and secreted from brain slices and astrocyte tumor cells. The results were obtained in tissue with defined experimental conditions, pharmacologically differentiated tools, and biological validation as assessed by thrombin activity measurement. FXa activity in neural tissue is tightly regulated and undetectable without an FX activator. KEY MESSAGES: We developed a sensitive method using fluorescence substrate to measure the fine changes in FXa activity in neural tissue. Brain slice associated FXa activity differs from secreted activity in its response to activators and inhibitors, suggesting the complexity of FXa activity regulation in neural tissue. Specific set of conditions is needed to detect FXa activity in neural tissue.

Indexed as

BrainFactor XFactor XaGliomaAnimalsBrain NeoplasmsCell Line, TumorFactor Xa InhibitorsHumansMaleMicePyrazolesPyridonesRatsSignal TransductionViper VenomsapixabanFactor XFactor XaFactor Xa InhibitorsPyrazolesPyridonesViper VenomsActivated Factor XActivityBrain tissueCoagulationFactor XGliomaInflammation

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.